MedPath

Stichting Centre for Human Drug Research (CHDR)

Stichting Centre for Human Drug Research (CHDR) logo
🇳🇱Netherlands
Ownership
Private
Established
1987-01-01
Employees
251
Market Cap
-
Website
http://www.chdr.nl

Clinical Trials

202

Active:34
Completed:123

Trial Phases

4 Phases

Phase 1:33
Phase 2:7
Phase 4:8
+1 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (60 trials with phase data)• Click on a phase to view related trials

Phase 1
33 (55.0%)
Not Applicable
12 (20.0%)
Phase 4
8 (13.3%)
Phase 2
7 (11.7%)
No trials found

News

Immutep's IMP761 Shows 80% T Cell Suppression in Phase I Autoimmune Disease Trial

Immutep's first-in-class LAG-3 agonist antibody IMP761 demonstrated 80% inhibition of T cell infiltration at 0.9 mg/kg dose with no treatment-related adverse events in healthy participants.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.